Tag: Precision oncology 2025

Home / Precision oncology 2025

Categories

Selpercatinib is approved by FDA for RET fusion-positive thyroid cancer

  May 2024: The Food and Drug Administration has officially approved selpercatinib (Retevmo, Eli Lilly and Company) for the treatment of advanced or metastatic RET fusion-positive thyroid canc...
precision-oncology-2025

Scan the code